Cowden's disease is an autosomal dominant disorder characterized by the development of multiple mucocutaneous lesions and benign tumors, and enhanced cancer predisposition.
Introduction
Cowden's disease is an autosomal dominant disorder characterized by the development of multiple mucocutaneous lesions and benign tumors, and by the predisposition to a variety of malignancies, particularly breast and thyroid cancers (1) (2) (3) (4) . The Cowden's disease gene locus has been mapped to the chromosome 10q22-23 in which the PTEN gene is located (5) (6) (7) (8) . PTEN encodes a lipid phosphatase, PTEN, which is a negative regulator of the phosphatidylinositol 3-kinase (PI3K) pathway by converting phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) into phosphatidylinositol 4,5-biphosphate (PIP 2 ; refs. [9] [10] [11] . Underscoring the importance of PTEN as a tumor suppressor gene, germline mutations of PTEN have been linked to several autosomal dominant hamartoma syndromes including Cowden's disease (Omim:308350), BannayanRiley-Ruvalcaba syndrome (OMIM:153480), and Lhermitte-Duclos syndrome (OMIM:158350), which are all characterized by the presence of benign tumors, known as hamartomas, in multiple organs and an increased susceptibility to developing a variety of malignancies (reviewed in ref. 12 ).
In the case of Cowden's disease, PTEN germline mutations are found in 80% of the patients, either in the PTEN coding sequence, in the PTEN promoter, or in its 5 ¶ and 3 ¶ untranslated region resulting in inhibition of translation or a catalytically inactive, immature, or unstable PTEN protein, which may undergo rapid degradation (10, 12) . Pten heterozygosity and tissue-specific deletion in mice leads to hyperplastic and dysplasic changes in the prostate, colon, and skin, and to spontaneous tumor development, supporting the notion that PTEN plays a causal role in hamartoma syndromes (13) (14) (15) (16) (17) (18) (19) . Cells exhibiting decreased PTEN activity are not able to restrain the growth promoting properties of PI3K and its lipid product, PIP 3 (10, 11, 20) . One of the best studied downstream targets of PI3K is the serine-threonine kinase Akt, which, upon activation by PIP 3 , promotes cell proliferation and survival by phosphorylating multiple protein targets, thereby controlling cell growth, protein translation, cell metabolism, and program cell death (21, 22) .
As Cowden's disease is characterized by the high incidence epithelial derived tumors, we selectively inactivated a floxed Pten allele in mice by the expression of Cre recombinase under the control of the keratin 14 (K14) promoter, which is expressed in hair follicles, glandular ducts, epidermis, and other epithelial cells (23, 24) . Although mice developed normally, and newborn mice did not exhibit any obvious phenotype, Pten deletion in epithelial cells led to the development of multiple dermal lesions and breast and thyroid tumors as age progressed, strikingly resembling Cowden's disease. This animal model provided an opportunity to explore the efficacy of interfering with the PI3K/Akt pathway as a therapeutic approach in this hamartoma syndrome. Indeed, we show here that the pharmacologic inhibition of one particular downstream target of Akt, mammalian target of rapamycin (mTOR), by the prolonged treatment with rapamycin promoted the rapid regression of advanced Cowden's disease-like lesions. Furthermore, we found that by initiating the chronic administration of rapamycin before the appearance of disease manifestation in mice, in which Pten has been conditionally deleted, was sufficient to prevent the development of Cowden's disease-like lesions, thereby prolonging remarkably animal survival. Thus, these findings suggest that the blockade of mTOR with rapamycin and its analogues may represent a suitable therapeutic option for the chemoprevention and treatment of Cowden disease's patients. Culture of primary keratinocytes and Western blotting. Murine keratinocytes were isolated as described (23) , grown in KBM-2 medium (Cambrex). After lyses, protein concentrations were determined and 30 g of proteins were separated on 10% SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% milk protein, and incubated with primary antibodies Akt, phospho-specific Akt (pAkt Ser473 and pAkt Thr308 ), and S6 (pS6; Cell Signaling Technology), PTEN (Cascade Bioscience), and tubulin (Santa Cruz Biotechnology), as previously described (27) . Western blot signals were quantitated by using the NIH Image J software. 1 Histology and immunohistochemistry of tissue sections. H&E staining was performed on formalin-fixed and paraffin-embedded 4-m serial sections according to standard procedures. Immunohistochemistry was performed on these paraffin-embedded and frozen tissue sections using antibodies pAkt Ser473 , pAkt Thr308 , pS6 (Cell Signaling Technology), and proliferating cell nuclear antigen (PCNA; Zymed Laboratories) as described previously (26, 28) . Quantitative analysis of the staining intensity was performed by using the NIH Image J software. Procedure periodic acidSchiff (PAS) staining (Sigma-Aldrich) was performed as described by the manufacturer.
Materials and Methods
Statistical analysis. Comparison of the Kaplan-Meier survival analysis was performed with the logrank test. Statistical analysis of the staining for PCNA, pAkt Ser473 , pAkt Thr308 , pS6, and the body weight was performed by ANOVA One-way, followed by the Bonferroni's multiple comparison tests using GraphPad Prism 4.03 (GraphPad Software).
Results
Excision of Pten recapitulates features of Cowden's disease. We generated epithelial-specific Pten conditional knockout mice by crossing mice harboring a floxed Pten allele containing two loxP sites (Pten F/F ) with mice expressing the Cre recombinase under the control of the K14 promoter (K14Cre). K14Cre Pten F/+ heterozygous mice were backcrossed with Pten F/F mice, and littermates that inherited some but not all of the above alleles served as controls. K14Cre Pten F/F mice were undistinguishable from the littermates at birth. However, at ages 6 days, the skin was wrinkled and flaky when compared with heterozygous K14Cre Pten F/+ and control mice, and by ages 11 days, the hair shafts had a disheveled appearance (data not shown). The animals progressively developed multiple hyperproliferative lesions, ranging from mucocutaneous lesions (95%; 41 of 44 mice) to tumor formation ( Fig. 1A ; Table 1 ). In particular, multiple papules rapidly developed around the facial orifices such as nose, mouth, and eyes (Fig. 1A, top) . Punctuate palmoplantar keratoses, acral keratosis, especially in the limbs and periauricular, and oral papules were also frequently observed (Fig. 1A, bottom) . Histologically, most facial and periauricular lesions had a follicular component with hyperproliferation of the outer root sheath, also evident in the vibrissae (Supplementary Fig. S1A ; ear and vibrissae). Papillomatous lesions of the skin presented hyperkeratosis and acanthosis throughout the face and body skin (Supplementary Fig. S1A ; skin and head). Acral extremities areas displayed verrucous and hyperkeratotic lesions also seen in the punctuate palmoplantar keratosis of the paws (Supplementary Fig. S1A ; paw).
Deletion of Pten compromises animal survival. Initially, the offspring from mating K14Cre Pten F/+ mice with Pten F/F mice followed the expected Mendelian distribution ( Supplementary  Fig. S2A ). Although rapid death was initially observed in K14Cre Supplementary  Fig. S2A ), their survival was much greater than observed when using Cre driven by the K5 promoter (14) . Although K14-and K5-driven gene expression are expected to have somehow overlapping tissue specificity (29) , K14Cre Pten F/F mice did not develop esophageal hyperplasia, which could compromise the survival of K5Cre mice. In addition, we were able to achieve an increase in animal survival of K14Cre Pten F/F mice by removing littermate competition and extending the weaning period ( Supplementary Fig. S2A ). Under these optimized breeding conditions, most animals survived until weaning, and 40% of the mice survived beyond ages 3 months, although the life span of K14Cre Pten F/F mice did not exceed 250 days ( Fig. 1B; Supplementary Fig. S2A ). Decreased survival was also present in heterozygous K14Cre Pten F/+ mice, which died or had to be sacrificed because of morbidity (Fig. 1B) . Nonetheless, the ability to extend the survival of K14Cre Pten F/F mice for up to ages 9 months enabled us to explore in detail the nature of the pathologic conditions caused by Pten deletion in the epithelial compartment of mice.
Hyperproliferative and tumoral lesions in K14Cre Pten F/F mice. As described above, several cutaneous lesions could be readily observed during examination of K14Cre Pten F/F mice. They include the unique presence of trichilemmomas, a pathognomonic sign of Cowden's Disease (2) that resembles blown-up hair follicles, which often exhibit cylindrical or lobular proliferation and PASpositive proliferating glycogen-rich clear cells ( Fig. 2A, top) . Besides numerous skin alterations, Cowden's disease is characterized by thyroid multinodular goiter, adenomas, and increased risk for thyroid cancer (4, 8) . Indeed, homozygous deletion of Pten resulted in alterations in the thyroid gland of K14Cre Pten F/F mice (n = 16), including multinodular goiters (56%; 9 of 16 mice analyzed) and thyroid tumors (12%; 2 of 16 mice analyzed) with a follicular aspect ( Fig. 2A, bottom ; Table 1 ). Patients harboring PTEN deletions and mutations also often develop fibroadenomas, fibrocystic disease, virginal hypertrophy of the breast, and malformations of nipples and areolae (3, 4, 30) . This was reflected in K14Cre Pten F/F mice, 80% (29 of 36 mice analyzed) of which displayed morphologic alterations in the nipples. Multiple mammary gland tumors were also observed in the thoracic and abdominal/inguinal mammary glands of K14Cre Pten F/F mice (11%; 4 of 36 mice analyzed; Fig. 2B ; Table 1 ). This was even more remarkable in K14Cre Pten F/+ mice (36%; 8 of 22 mice analyzed), as their extended survival enabled the development of larger tumoral lesions. In both cases, lesions were characterized by the presence of prominent intraluminal and ductal proliferation (Fig. 2B, b) . Histologic features of breast tumors ranged from fibroadenomas (Fig. 2B, c) to adenocarcinomas and ductal carcinomas with dense hyaline collagen or dense fibrosis replacing the intralobular stroma (Fig. 2B, e and f ) .
Reversion of Cowden's disease-like lesions by mTOR inhibition. Activation of Akt involves its recruitment to the membrane by binding PIP 3 and the initial phosphorylation of threonine 308 (Thr308) in its activation loop by PDK1 (22, 31) . Subsequently, Akt is phosphorylated in serine 473 (Ser473) by one of its downstream targets, the atypical kinase mTOR, thereby increasing its activity (31) . mTOR in turn regulates protein translation by phosphorylating 4EBP, an inhibitor of the translational initiation protein eIF4E, and p70S6K, which phosphorylates the S6 ribosomal protein (32, 33) . Recent studies have indicated that the activation of the PI3K-Akt-mTOR signaling axis represents a key proliferative pathway shared by multiple solid tumors (21, 22, 34, 35) . Thus, we took advantage of the ability to block mTOR function in vivo by the use of its specific inhibitor, rapamycin (36) , to explore the contribution of mTOR activity to the development of Cowden's disease-like lesions in K14Cre Pten F/F mice. As shown in Fig. 3A , the treatment of symptomatic K14Cre Pten F/F adult mice (n = 4) for only 9 days with a clinical relevant dose of rapamycin (1 mg/kg; every other day; ref. 37) caused the regression of wellestablished mucocutaneous lesions, which was readily visible in the face and paws.
Rapamycin treatment clearly diminished the activity of mTOR in vivo, as judged by the dramatically reduced immunohistochemical detection of the phosphorylated form of S6, which was elevated in K14Cre Pten F/F mice when compared with littermate controls ( Fig. 3B; Supplementary Fig. S2B ). The reduced pS6 levels reflected the inhibition of mTOR as part of its complex 1 (mTORC1), the direct target of rapamycin (38) , thus representing a suitable marker for monitoring the activity of rapamycin on its target molecule (see refs. 39-41, and references therein). Concomitantly, rapamycin reduced the proliferation of epithelial cells within the skin lesions, as assessed by PCNA staining ( Fig. 3B; Supplementary Fig. S2B ), which was quite elevated in Pten-deficient mice when compared with controls (P < 0.001). Aligned with the elevated levels of PI3K lipid products in these Pten-deficient mice, there was an extensive accumulation of Akt phosphorylated in its Ser473 site (pAkt Ser473 ) in the skin of the vehicle-treated K14Cre Pten F/F animals ( Fig. 3B,  top; Supplementary Fig. S2B ). Prolonged treatment with rapamycin resulted in a decreased phosphorylation of pAkt Ser473 ( Fig. 3B;  Supplementary Fig. S2B ). This is likely due to the indirect inhibition of the mTOR 2 complex (mTORC2), which phosphorylates Akt on its Ser 473 site, which represents a secondary effect of rapamycin previously described to occur in vivo (38) . However, there appeared to be an increased level of pAkt Thr380 after rapamycin treatment, which also shifted from the nucleus in the K14Cre Pten F/F animals to the membrane. These observations suggest that upon mTOR blockade, the activity of Akt may be enhanced, likely due to the absence of a negative feedback mechanism restraining growth factor activation of Akt (38) , similar to that reported during recent clinical trials with rapamycin in PTEN-deficient glioblastoma patients (41) . Of interest, however, this active Akt may not be able to be released from the membrane in cells that accumulate PIP 3 due to the absence of Pten phosphatase activity, as judged by its membrane accumulation (Fig. 3B, middle) .
Elevated levels of pS6 and the effect of rapamycin on pAkt
Thr308
were also observed in primary cultures of keratinocytes isolated from K14Cre Pten F/F mice. As expected, Pten levels were reduced in cells isolated from heterozygous K14Cre Pten F/+ mice, and almost absent in keratinocytes from K14Cre Pten F/F homozygous mice. , pAkt Ser473 , pS6, and PCNA in the epithelium from control and K14Cre Pten F/F mice treated with vehicle or rapamycin. Note the elevated phosphorylation of pS6 and Akt in Ser473, and PCNA in K14Cre Pten F/F mice. Upon treatment, pS6, pAkt Ser473 levels, and PCNA nuclear staining were notably reduced. pAkt
, which is present in the nucleus of epithelial cells in K14Cre Pten F/F mice, shifted to the membrane in rapamycin-treated mice. C, representative Western blot analysis of primary culture from mice for molecules whose activity is regulated by PTEN and tubulin, as a loading control, in lysates from primary cultures of keratinocytes isolated from control (c ), K14Cre Pten F/+ (f/+), and K14Cre Pten F/F (f/f ) mice (n = 3 independent experiment per genotype). Cells were treated with vehicle or rapamycin, as indicated. PTEN levels were reduced in K14Cre Pten F/+ and almost absent in K14Cre Pten , and pS6, represented as the average F SE (n = 3) normalized by the total amount of protein and displayed as fold increase of the control mice (C, bottom, white bar ). We observed increased levels of both pAkt Ser473 and pS6 in K14Cre Pten F/F homozygous mice. Rapamycin treatment lead to a complete ablation of S6 phosphorylation, although it had only a limited effect on pAkt Ser473 levels, aligned again with the direct effect of rapamycin on the mTORC1 complex after short time treatment. However, rapamycin provoked an increase in pAkt Thr308 in primary cultures from Pten-deficient mice when compared with those derived from heterozygous and control mice (Fig. 3C) . Thus, the effects of rapamycin on signaling events in the epithelial compartment of the skin of K14Cre Pten F/F mice likely represent a primary effect on the targeted cells, rather than resulting from alterations caused by mTOR inhibition in the stroma.
Rapamycin as a chemoprevention agent for experimental Cowden's disease. Over 90% of individuals affected with Cowden's disease are believed to manifest clinical signs of the disease by the ages 20 years; 99% of the affected individuals develop mucocutaneous lesions by the end of the third decade, although other clinical manifestations may be present; and tumor formation is usually detected at the beginning of the fourth decade ( Fig. 4; refs. 1-4). Of interest, as mice age, K14Cre Pten F/F animals acquired a phenotype that closely resembles the progression of Cowden's disease ( Fig. 4 ; Table 1 ). Thus, we asked whether rapamycin administration before the appearance of disease manifestation could prevent the development of Cowden's disease-like lesions in mice already harboring Pten deletions. For these experiments, we administered a clinically relevant low dose of rapamycin (37) starting at ages 5 days, and compared disease progression in the treated animals to their littermate controls (n = 13 per group). There were no statistically significant differences in the body weight when comparing control mice treated with the rapamycin inhibitor and vehicle (Fig. 4C) . The K14Cre Pten F/F mice treated with vehicle (20.9 F 2.8 g) were slightly smaller then their control littermates (28.1 F 2.9 g) but gained weight similar to control mice upon rapamycin treatment (24.1 F 2.5 g; Fig. 4C ). Furthermore, rapamycin treatment prevented the development of dermatologic lesions, including facial papules, oral papules, acral, and palmoplantar keratoses, and increased the life span of K14Cre Pten F/F mice ( Fig. 4A and B) . This reduction in the mortality of K14Cre Pten F/F mice was quite remarkable (vehicle control: median survival, 94 days; rapamycin: median survival, >320 days; P > 0.0001; Fig. 4B ), suggesting that mTOR inhibition may represent a suitable chemopreventive strategy to halt Cowden's disease progression (Fig. 4D) .
Discussion
Cowden's disease was named after the first described patient, Rachael Cowden, in 1963 (1). The discovery of PTEN germline , and K14Cre Pten F/F (n = 13 for each genotype). A, whereas K14Cre Pten F/F mice formed lesions, K14Cre Pten F/F from the same litter that were treated with rapamycin did not develop dermatologic lesions. Representative mice are depicted. B, survival curve (Kaplan-Meier survival analysis) of animals treated with vehicle and rapamycin. Rapamycin extended the survival of K14Cre Pten F/+ and K14Cre Pten F/F mice (logrank test between K14Cre Pten F/F treated with vehicle and rapamycin, P < 0.0001). C, growth curves of animals treated with vehicle and rapamycin (n = 13 mice per genotype). Points, mean; bars, SE. There were no statistically significant differences in the body weight among any of the indicated groups (P > 0.05). D, cartoon depicting the chronological development of Cowden's disease clinical manifestations during the lifetime in humans harboring inactivating PTEN mutations and deletions, and epithelial Pten -deleted mice. Arrows, initiation of rapamycin treatment for the chemoprevention (red ) or therapy (orange ) of experimental Cowden's disease in mice.
somatic mutations in the majority of Cowden's disease patients have provided an opportunity for the early diagnosis to individuals that are susceptible to the development of this debilitating and cancer-prone syndrome (5) (6) (7) (8) . Aligned with the key role of PTEN in Cowden's disease syndrome, we were able to recapitulate most of the pathognomonic lesions characterizing Cowden's disease, including trichilemmoma, acral keratoses, papillomatous, and mucosal lesions, and even breast and thyroid alterations and tumors by deleting Pten in stratified and ductal epithelial cells using K14Cre mice, which was combined with the optimization of the housing conditions to extend the life span of the affected mice. The availability of this animal model provided a unique opportunity to explore the ability to interfere with PTEN downstream molecules as potential targets for therapeutic intervention in Cowden's disease.
Reduced PTEN function, and thus elevated PIP 3 accumulation, can result in altered activity of a PI3K-depedent signaling network, which ultimately promotes disease progression (21, 22) . Although inhibiting PI3K activity would be a good candidate to limit PIP 3 , and as a result compensate for PTEN reduced activity, currently, PI3K inhibitors may have undesirable side effects that limit their clinical use (42) . Among the many biochemical routes regulated by PI3K, the Akt-mTOR pathway has recently emerged as a key component of proliferative pathways activated downstream from PI3K and PTEN (34, 35, 43) . In this regard, loss of mTOR is epistatic to Pten loss in drosophila megalogaster (44, 45) . Furthermore, the oncogenic activity of Akt seems to be dependent on mTOR, and many sporadic tumors involving PTEN deletions and inactivating mutations are highly sensitive to rapamycin treatment that blocks mTOR (43, 46, 47) . Indeed, we observed elevated activity of Akt and mTOR in hyperproliferative lesions resulting from Pten deletion. Thus, considering that prophylactic mastectomy is often recommended (48) and there is no approved therapy available for Cowden's disease, we explored the consequences of mTOR inhibition with rapamycin in this genetically defined animal model. We observed that rapamycin treatment can rapidly revert the mucocutaneous papillomatous lesions in the face and limbs, acral keratosis, and deformities of nipples, among others, concomitant with a marked decreased of the elevated levels of pS6, which served as a suitable biomarker of drug efficacy in the target tissues. Furthermore, the early treatment with rapamycin prevented the development of Cowden's disease-like lesion in mice in which Pten was excised, thus dramatically increasing their life expectancy.
The use of rapamycin has been approved by the Food and Drug Administration (FDA) in 1999 to prevent renal transplantation rejection (49) . Since then, many analogues of rapamycin have been developed, some of which have increased bioavailability and are well-tolerated with reduced side effects, including lack of immunesuppressive activity at doses that are effective in blocking mTOR (35, 49) . Rapamycin (41) and many of its analogues (rapalogs), including CCI-779 (temsirolimus), RAD001 (everolimus), and AP23573, are in clinical trials for a variety of tumor types, and CCI-779 has been recently approved by FDA for the treatment of renal carcinoma patients (50) . Collectively, the extensive experience with the use of rapalogs in the clinic and the key role of mTOR in Cowden's disease progression may provide the rationale for the early clinical evaluation of rapamycin and its analogues as a molecular-targeted chemopreventive strategy for Cowden's disease and others tumor syndromes that involve defective PTEN function.
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